191 related articles for article (PubMed ID: 36769196)
1. miR-383-5p, miR-181a-5p, and miR-181b-5p as Predictors of Response to First-Generation Somatostatin Receptor Ligands in Acromegaly.
Henriques DG; Miranda RL; Dezonne RS; Wildemberg LE; Camacho AHDS; Chimelli L; Kasuki L; Lamback EB; Guterres A; Gadelha MR
Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769196
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA in Acromegaly: Involvement in the Pathogenesis and in the Response to First-Generation Somatostatin Receptor Ligands.
Henriques DG; Lamback EB; Dezonne RS; Kasuki L; Gadelha MR
Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955787
[TBL] [Abstract][Full Text] [Related]
3. Immunological signatures and predictive biomarkers for first-generation somatostatin receptor ligand resistance in Acromegaly.
Luo M; Yu J; Tang R
J Neurooncol; 2024 May; 167(3):415-425. PubMed ID: 38441839
[TBL] [Abstract][Full Text] [Related]
4. Multivariable Prediction Model for Biochemical Response to First-Generation Somatostatin Receptor Ligands in Acromegaly.
Coopmans EC; Korevaar TIM; van Meyel SWF; Daly AF; Chanson P; Brue T; Delemer B; Hána V; Colao A; Carvalho D; Jaffrain-Rea ML; Stalla GK; Fajardo-Montañana C; Beckers A; van der Lely AJ; Petrossians P; Neggers SJCMM
J Clin Endocrinol Metab; 2020 Sep; 105(9):. PubMed ID: 32589751
[TBL] [Abstract][Full Text] [Related]
5. Genome wide analysis of circulating miRNAs in growth hormone secreting pituitary neuroendocrine tumor patients' plasma.
Niedra H; Peculis R; Litvina HD; Megnis K; Mandrika I; Balcere I; Romanovs M; Steina L; Stukens J; Breiksa A; Nazarovs J; Sokolovska J; Liutkeviciene R; Vilkevicute A; Konrade I; Rovite V
Front Oncol; 2022; 12():894317. PubMed ID: 36158656
[TBL] [Abstract][Full Text] [Related]
6. Machine Learning-based Prediction Model for Treatment of Acromegaly With First-generation Somatostatin Receptor Ligands.
Wildemberg LE; da Silva Camacho AH; Miranda RL; Elias PCL; de Castro Musolino NR; Nazato D; Jallad R; Huayllas MKP; Mota JIS; Almeida T; Portes E; Ribeiro-Oliveira A; Vilar L; Boguszewski CL; Winter Tavares AB; Nunes-Nogueira VS; Mazzuco TL; Rech CGSL; Marques NV; Chimelli L; Czepielewski M; Bronstein MD; Abucham J; de Castro M; Kasuki L; Gadelha M
J Clin Endocrinol Metab; 2021 Jun; 106(7):2047-2056. PubMed ID: 33686418
[TBL] [Abstract][Full Text] [Related]
7. Molecular determinants of enhanced response to somatostatin receptor ligands after debulking in large GH-producing adenomas.
Gil J; Marques-Pamies M; Jordà M; Fajardo-Montañana C; García-Martínez A; Sampedro M; Serra G; Salinas I; Blanco A; Valassi E; Sesmilo G; Carrato C; Cámara R; Lamas C; Casano-Sancho P; Alvarez CV; Bernabéu I; Webb SM; Picó A; Marazuela M; Puig-Domingo M;
Clin Endocrinol (Oxf); 2021 May; 94(5):811-819. PubMed ID: 32978826
[TBL] [Abstract][Full Text] [Related]
8. Clinical Management of Acromegaly: Therapeutic Frontiers and New Perspectives for Somatostatin Receptor Ligands (SRLs).
Brunetti A; Antonini S; Saladino A; Lavezzi E; Zampetti B; Cozzi R
Medicina (Kaunas); 2022 Jun; 58(6):. PubMed ID: 35744057
[TBL] [Abstract][Full Text] [Related]
9. Effects of active acromegaly on bone mRNA and microRNA expression patterns.
Belaya Z; Grebennikova T; Melnichenko G; Nikitin A; Solodovnikov A; Brovkina O; Grigoriev A; Rozhinskaya L; Lutsenko A; Dedov I
Eur J Endocrinol; 2018 Apr; 178(4):353-364. PubMed ID: 29374071
[TBL] [Abstract][Full Text] [Related]
10. Circulating miR-29c-3p is downregulated in patients with acromegaly.
Korkmaz H; Hekimler Öztürk K; Torus B
Turk J Med Sci; 2021 Aug; 51(4):2081-2086. PubMed ID: 34013701
[TBL] [Abstract][Full Text] [Related]
11. Growth hormone granulation pattern and somatostatin receptor subtype 2A correlate with postoperative somatostatin receptor ligand response in acromegaly: a large single center experience.
Brzana J; Yedinak CG; Gultekin SH; Delashaw JB; Fleseriu M
Pituitary; 2013 Dec; 16(4):490-8. PubMed ID: 23184260
[TBL] [Abstract][Full Text] [Related]
12. Somatostatin receptor expression and patients' response to targeted medical treatment in pituitary tumors: evidences and controversies.
Gatto F; Arvigo M; Ferone D
J Endocrinol Invest; 2020 Nov; 43(11):1543-1553. PubMed ID: 32557353
[TBL] [Abstract][Full Text] [Related]
13. The Multibiomarker Acro-TIME Score Predicts fg-SRLs Response: Preliminary Results of a Retrospective Acromegaly Cohort.
Chiloiro S; Moroni R; Giampietro A; Angelini F; Gessi M; Lauretti L; Mattogno PP; Calandrelli R; Tartaglione T; Carlino A; Gaudino S; Olivi A; Rindi G; De Marinis L; Pontecorvi A; Doglietto F; Bianchi A
J Clin Endocrinol Metab; 2024 Apr; 109(5):1341-1350. PubMed ID: 37975821
[TBL] [Abstract][Full Text] [Related]
14. Circulating Plasma MicroRNA in Patients With Active Acromegaly.
Lutsenko A; Belaya Z; Nikitin A; Solodovnikov A; Lapshina A; Koshkin P; Vorontsova M; Rozhinskaya L; Melnichenko G; Dedov I
J Clin Endocrinol Metab; 2022 Jan; 107(2):500-511. PubMed ID: 34550352
[TBL] [Abstract][Full Text] [Related]
15. Clinical and Radiological Predictors of Biochemical Response to First-Line Treatment With Somatostatin Receptor Ligands in Acromegaly: A Real-Life Perspective.
Nista F; Corica G; Castelletti L; Khorrami K; Campana C; Cocchiara F; Zoppoli G; Prior A; Rossi DC; Zona G; Ferone D; Gatto F
Front Endocrinol (Lausanne); 2021; 12():677919. PubMed ID: 34025586
[TBL] [Abstract][Full Text] [Related]
16. Predictive Factors of Somatostatin Receptor Ligand Response in Acromegaly-A Prospective Study.
Ilie MD; Tabarin A; Vasiljevic A; Bonneville JF; Moreau-Grangé L; Schillo F; Delemer B; Barlier A; Figarella-Branger D; Bisot-Locard S; Santos A; Chanson P; Raverot G
J Clin Endocrinol Metab; 2022 Nov; 107(11):2982-2991. PubMed ID: 36136828
[TBL] [Abstract][Full Text] [Related]
17. The Future of Somatostatin Receptor Ligands in Acromegaly.
Gadelha MR; Wildemberg LE; Kasuki L
J Clin Endocrinol Metab; 2022 Jan; 107(2):297-308. PubMed ID: 34618894
[TBL] [Abstract][Full Text] [Related]
18. Serum miR-1228-3p and miR-181a-5p as Noninvasive Biomarkers for Non-Small Cell Lung Cancer Diagnosis and Prognosis.
Xue WX; Zhang MY; Rui Li ; Liu X; Yin YH; Qu YQ
Biomed Res Int; 2020; 2020():9601876. PubMed ID: 32724822
[TBL] [Abstract][Full Text] [Related]
19. Pasireotide in the Personalized Treatment of Acromegaly.
Puig-Domingo M; Bernabéu I; Picó A; Biagetti B; Gil J; Alvarez-Escolá C; Jordà M; Marques-Pamies M; Soldevila B; Gálvez MA; Cámara R; Aller J; Lamas C; Marazuela M
Front Endocrinol (Lausanne); 2021; 12():648411. PubMed ID: 33796079
[TBL] [Abstract][Full Text] [Related]
20. Normal Insulin-like Growth Factor 1 During Somatostatin Receptor Ligand Treatment Predicts Surgical Cure in Acromegaly.
Losa M; Garbin E; Pedone E; Mortini P
J Clin Endocrinol Metab; 2020 Sep; 105(9):. PubMed ID: 32609842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
